A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Last updated: June 12, 2024
Sponsor: Takeda
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemophilia

Treatment

Susoctocog Alfa (Genetical Recombination)

Clinical Study ID

NCT06461533
TAK-672-4004
  • All Genders

Study Summary

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.

During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Susoctocog Alfa (Genetical Recombination)
Phase:
Study Start date:
June 10, 2024
Estimated Completion Date:
October 31, 2029

Connect with a study center

  • Takeda selected site

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.